P-CD19 x CD20 - ALLO1

N/A

Report date: 2024/11/18 10:43:28

Base Information

Drug NameP-CD19 x CD20 - ALLO1
Drug Alias NameRG6540RG-6540
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 modulators +[4] 
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche LtdPoseida Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdPoseida Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A